VPHIF / Valeo Pharma enters commercialization and supply agreement with Novartis Canada for two ophthalmic therapies

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) CEO Steve Saviuk joined Proactive's Stephen Gunnion to discuss the company's strong position on the Globe an more_horizontal

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) highlighted to investors that it has placed at spot 151 on the Globe and Mail's Report on Business annual lis more_horizontal

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported its seventh consecutive rise in revenues to a quarterly record due to strong growth in its Enerz more_horizontal

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has closed a non-brokered private placement offering, raising gross proceeds of $3.92 million. The company a more_horizontal

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said Tamara Close and Didier Leconte have both joined its board of directors, noting that following the appo more_horizontal

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) has reported record quarterly revenues of $13.6 million for its second quarter ending April 30, 2023, repr more_horizontal

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said it expects revenues in the second quarter to exceed $13.5 million, a quarterly record, with operating ex more_horizontal

Valeo Pharma Inc. (TSX:VPH, OTCQB:VPHIF) said its revenue for the first quarter ended January 31, 2023, rose by 210% to a record $13.2 million, up fro more_horizontal